AstraZeneca Advances Tagrisso Combination in Lung Cancer, Discontinues Volrustomig Trial
AstraZeneca (LON: AZN) issued two contrasting oncology updates on Monday 17 August 2026, revealing a win for one lung cancer combination therapy alongside the discontinuation of a separate late-stage trial.…